Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder

Kiyokazu Atake, Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Jun Nakamura Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan Purpose: This study investigated the relationships among the plasma levels of catecholamine metabolites, the clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Atake K, Yoshimura R, Hori H, Katsuki A, Nakamura J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/cb00d7a23f6f452086acb0603aabc9da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb00d7a23f6f452086acb0603aabc9da
record_format	dspace
spelling	oai:doaj.org-article:cb00d7a23f6f452086acb0603aabc9da2021-12-02T07:14:49ZCatechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder1178-2021https://doaj.org/article/cb00d7a23f6f452086acb0603aabc9da2015-04-01T00:00:00Zhttp://www.dovepress.com/catechol-o-methyltransferase-val158met-genotype-and-the-clinical-respo-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Kiyokazu Atake, Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Jun Nakamura Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan Purpose: This study investigated the relationships among the plasma levels of catecholamine metabolites, the clinical response to duloxetine treatment, and Val158Met polymorphism of the catechol-O-methyltransferase (COMT) gene. Subjects and methods: Sixty-four patients and 30 healthy control subjects were recruited. Major depressive episodes were diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD17). Patients whose HAMD17 scores were 15 or greater were enrolled in the study. Blood sampling and clinical evaluation were performed at week 0 and week 8. The levels of plasma catecholamine metabolites were measured using high-performance liquid chromatography with electrochemical detection. Genotyping was performed using direct sequencing. Results: Thirty of 45 patients (67%) responded to duloxetine treatment during the 8 weeks of treatment. The baseline plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), but not homovanillic acid (HVA), were lower in patients with major depressive disorder (MDD) who had the Val/Val genotype than in patients who were Met-carriers. Patients with MDD and the Val/Val genotype, but not Met carriers, had increased plasma levels of MHPG after 8 weeks of duloxetine treatment. The baseline plasma MHPG levels in healthy control subjects with the Val/Val genotype were significantly higher than those in patients with MDD. Among the subjects in the MDD group with the Val/Val genotype, the plasma MHPG levels increased to the same degree as in the healthy control subjects with the Val/Val genotype after 8 weeks of duloxetine treatment. Conclusion: The relationship among the COMT Val158Met polymorphism, plasma levels of catecholamine metabolites, and responses to duloxetine is complex. Nevertheless, our results suggest that patients with MDD and the Val/Val genotype are more sensitive to the influence of noradrenergic neurons by duloxetine treatment. Keywords: major depressive disorder, duloxetine, catechol-O-methyltransferase, 3-methoxy-4-hydroxyphenylglycol, homovanillic acidAtake KYoshimura RHori HKatsuki ANakamura JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 967-974 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Atake K Yoshimura R Hori H Katsuki A Nakamura J Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
description	Kiyokazu Atake, Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Jun Nakamura Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan Purpose: This study investigated the relationships among the plasma levels of catecholamine metabolites, the clinical response to duloxetine treatment, and Val158Met polymorphism of the catechol-O-methyltransferase (COMT) gene. Subjects and methods: Sixty-four patients and 30 healthy control subjects were recruited. Major depressive episodes were diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD17). Patients whose HAMD17 scores were 15 or greater were enrolled in the study. Blood sampling and clinical evaluation were performed at week 0 and week 8. The levels of plasma catecholamine metabolites were measured using high-performance liquid chromatography with electrochemical detection. Genotyping was performed using direct sequencing. Results: Thirty of 45 patients (67%) responded to duloxetine treatment during the 8 weeks of treatment. The baseline plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), but not homovanillic acid (HVA), were lower in patients with major depressive disorder (MDD) who had the Val/Val genotype than in patients who were Met-carriers. Patients with MDD and the Val/Val genotype, but not Met carriers, had increased plasma levels of MHPG after 8 weeks of duloxetine treatment. The baseline plasma MHPG levels in healthy control subjects with the Val/Val genotype were significantly higher than those in patients with MDD. Among the subjects in the MDD group with the Val/Val genotype, the plasma MHPG levels increased to the same degree as in the healthy control subjects with the Val/Val genotype after 8 weeks of duloxetine treatment. Conclusion: The relationship among the COMT Val158Met polymorphism, plasma levels of catecholamine metabolites, and responses to duloxetine is complex. Nevertheless, our results suggest that patients with MDD and the Val/Val genotype are more sensitive to the influence of noradrenergic neurons by duloxetine treatment. Keywords: major depressive disorder, duloxetine, catechol-O-methyltransferase, 3-methoxy-4-hydroxyphenylglycol, homovanillic acid
format	article
author	Atake K Yoshimura R Hori H Katsuki A Nakamura J
author_facet	Atake K Yoshimura R Hori H Katsuki A Nakamura J
author_sort	Atake K
title	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
title_short	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
title_full	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
title_fullStr	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
title_full_unstemmed	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
title_sort	catechol-o-methyltransferase val158met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in japanese patients with major depressive disorder
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/cb00d7a23f6f452086acb0603aabc9da
work_keys_str_mv	AT atakek catecholomethyltransferaseval158metgenotypeandtheclinicalresponsestoduloxetinetreatmentorplasmalevelsof3methoxy4hydroxyphenylglycolandhomovanillicacidinjapanesepatientswithmajordepressivedisorder AT yoshimurar catecholomethyltransferaseval158metgenotypeandtheclinicalresponsestoduloxetinetreatmentorplasmalevelsof3methoxy4hydroxyphenylglycolandhomovanillicacidinjapanesepatientswithmajordepressivedisorder AT horih catecholomethyltransferaseval158metgenotypeandtheclinicalresponsestoduloxetinetreatmentorplasmalevelsof3methoxy4hydroxyphenylglycolandhomovanillicacidinjapanesepatientswithmajordepressivedisorder AT katsukia catecholomethyltransferaseval158metgenotypeandtheclinicalresponsestoduloxetinetreatmentorplasmalevelsof3methoxy4hydroxyphenylglycolandhomovanillicacidinjapanesepatientswithmajordepressivedisorder AT nakamuraj catecholomethyltransferaseval158metgenotypeandtheclinicalresponsestoduloxetinetreatmentorplasmalevelsof3methoxy4hydroxyphenylglycolandhomovanillicacidinjapanesepatientswithmajordepressivedisorder
_version_	1718399541471870976

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder

Ejemplares similares